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ABSTRACT  
Genetically encoded fluorescent protein (FP)-based biosensor probes are useful tools for 
monitoring cellular events in living cells and tissues. Because these probes were developed for 
one-photon excitation approaches, their broad two-photon excitation (2PE) and poorly 
understood photo-bleaching characteristics have made their implementation in studies using 
two-photon laser-scanning microscopy (TPLSM) challenging.  Here, we describe a protocol that 
simplifies the use of Förster Resonance Energy Transfer (FRET)-based biosensors in TPLSM.  
First, the TPLSM system is evaluated and optimized using FRET standards expressed in living 
cells, which enables the determination of spectral bleedthrough and the confirmation of FRET 
measurements from the known standards. Then, we describe how to apply the approach 
experimentally using a modified version of the AKAR protein kinase A (PKA) biosensor as an 
example, first in cells in culture, and then in hepatocytes in the liver of living mice.  The 
microscopic imaging can be accomplished in a day in laboratories that routinely use TPLSM. 
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INTRODUCTION 
The use of TPLSM imaging to monitor the signals from biosensor proteins in living 
animals is of interest to many laboratories because it allows noninvasive detection of spatial and 
temporal characteristics of specific cell signaling or metabolic events.  These genetically 
encoded biosensor proteins contain reporter modules that typically consist of fluorescent 
proteins (FPs) directly linked to sensing units that detect specific cellular events1.  Many 
biosensor probes rely on Förster resonance energy transfer (FRET) to report the changes in 
protein conformation that occur in response to the cellular event1-6.  There are, however, 
significant challenges to the use of TPLSM to detect the FRET signals from biosensor probes in 
intact tissues, which fall into three general categories: 1) issues related to the two-photon 
excitation (2PE) characteristics of the biosensor probes, 2) difficulties in expressing the 
genetically encoded biosensors in the desired cell-type in living animals, and 3) problems 
associated with conducting high-resolution microscopy in living animals.  These three 
challenges are discussed further below, but this Protocol specifically addresses the first issue: 
identification, characterization, and validation of a FRET-based FP biosensor suitable for 
TPLSM in intact tissues.   
1) Optimized probes for TPLSM.  Many existing biosensor probes that were developed for 
one-photon excitation may perform poorly (or not at all) under 2PE.  Even those probes that 
perform well under 2PE may not be efficiently excited by the narrow range of wavelengths 
accessible with the titanium sapphire lasers used in most TPLSM systems (tunable from 690 to 
1040 nm, but peaking between 750 and 850 nm).  Many biosensor assays are based upon 
ratiometric measurements of images collected using two different excitation wavelengths.  This 
complicates measurements by TPLSM because most FPs have broad two-photon cross-sections, 
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limiting the ability to selectively excite one or the other FP.  Furthermore, most TPLSM 
systems are equipped with a single infrared laser, so the collection of ratiometric FRET 
measurements may require re-tuning of the laser between image acquisitions; a process that is 
slow (precluding dynamic studies), and introduces measurement errors because of changes in 
laser alignment.  Finally, photobleaching processes that occur under 2PE are poorly understood.  
Unlike single-photon excitation, the rate of photobleaching under 2PE increases exponentially 
with illumination power, sometimes increasing with the 3rd or 4th power of the illumination 
level7,8.  Since differences in the susceptibility of the donor- and acceptor-FPs to photobleaching 
could affect ratiometric measurements, it is particularly important to use FPs that are photo-
stable and free from photo-switching behavior. 
2) In vivo expression of FP biosensors.  The sequences that encode the biosensor probes are 
easily incorporated into plasmid or viral vectors that allow their transfer into living cells or 
organisms.  The use of suitable cell-type specific promoters can restrict the expression of the 
biosensors to specific tissues, and the probes can be directed to specific subcellular organelles 
by incorporating suitable targeting sequences.  The fluorescence signals from biosensor probes 
have been successfully imaged in a wide variety of organisms.  For example, transgenic C. 
elegans, Drosophila, and Zebrafish have been generated that express calcium sensing biosensor 
proteins9-11.  In general, the imaging of biosensor activities in transgenic mice, however, has 
proven to be more difficult12.  A problem often encountered with transgenes stably integrated in 
mice is low-level expression resulting from transgene silencing or recombination events that 
occur between the highly homologous sequences encoding the sensor FPs13,14.  Transgenic mice 
generated by transposon-mediated gene transfer methods have been reported to have higher 
levels of biosensor expression13-15.  Transgenic biosensor mice that express a variety of different 
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probes, including sensors of chloride16, calcium17,18, and voltage19, are available commercially 
(The Jackson Laboratory, Bar Harbor, ME) and might be useful for specific intravital imaging 
applications.  Transgenic mice expressing fluorescent biosensors for PKA, Erk, Rac, Ras are 
also available from the National Institutes of Biomedical Innovation, Health and Nutrition 
(Osaka, Japan).  Further, there are published studies reporting transgenic biosensor mice with 
ubiquitous tissue distribution13,19, or restricted tissue expression12.  The critical question for 
investigators is whether the biosensor expression is sufficiently high in the desired tissue in a 
particular mouse model to obtain unambiguous measurements of changing cell signaling 
events12. 
 Viral transduction is an alternative approach that offers rapid biosensor probe expression 
in living animals without the need for lengthy breeding strategies to achieve stable expression.  
The challenge for in vivo administration of viral vectors, however, is to obtain expression of the 
biosensor probes in the relevant cell types.  The expression of probes in a particular tissue can 
be achieved using cell-type specific promoters that restrict the biosensor expression to the target 
cells.  However, if the cells of interest can be identified based on morphology, it might not be 
necessary to achieve selective expression in specific cell populations.  Further, the systemic 
administration of unmodified adenovirus (Ad) generally results in the accumulation of the 
transgene in the liver and spleen20, so the tropism to these organs can be exploited for imaging 
studies.  
3) High resolution microscopy in living animals.  Intact, living organisms present unique 
challenges for microscopy.  First, the physiological welfare of the animal must be maintained 
and continuously monitored while the animal is on the microscope stage.  Second, in most 
cases, the tissue of interest must be surgically exposed, requiring the development of methods 
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for anesthesia and delicate surgery.  Third, the tissue must be immobilized so that motion 
induced by respiration and the heartbeat is reduced to sub-micron levels.   
The solutions to these challenges vary depending on the equipment used and the 
particular organ to be imaged.  In our studies of kidney and liver21-24, an inverted microscope 
stand is used to image the surgically exposed organs that are secured to a glass-bottomed dish 
(see Figure 1).  The anesthetized animal is placed on the microscope stage, and the animal’s 
temperature is maintained using a heating pad and monitored using a rectal thermometer.  
Generally, tissue motion can be minimized by careful placement of the tissue, and can be 
reduced further by bonding small regions of the tissue to the coverglass with cyanoacrylate 
adhesive.  Additionally, gating the image collection to respiration can minimize the motion 
artifacts in tissues such as the lung25,26.  Finally, motion-induced distortions can be eliminated 
from the collected images using various methods of digital image analysis27-31. 
Quantitative intravital microscopy is also complicated by the inevitable loss of signal 
that occurs when imaging into highly scattering biological tissues.  Therefore, the intensity 
measurements obtained from different depths cannot be directly compared.  In this regard, using 
FRET-based biosensors can be advantageous.  The ratio images obtained from biosensors will 
be minimally affected by depth provided that the scattering and absorption does not vary 
significantly for the emission wavelengths of the probe.  While we find no evidence of a 
significant effect of depth on FRET measurements obtained in vivo, minor effects were 
observed in other studies32.  Therefore, biosensor measurements collected over a large range of 
depths should be evaluated for systematic effects of depth on the FRET ratio.  In general, the 
effects of depth on ratiometric measures can be minimized by using non-descanned detectors 
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that are less susceptible to the effects of light scatter, and by avoiding FPs with widely different 
emission spectra. 
 
Development of the Protocol   
Previously, we described the characterization of FPs for FRET biosensor probes specifically 
intended for intravital imaging using TPLSM33.  Since the cyan FPs (CFP) are optimally excited 
close to the power maximum of the titanium-sapphire lasers used in most TPLSM systems, we 
focused our evaluations of potential FRET donors on the newer variants of the CFPs that have 
improved brightness and photostability, and no photo-switching behavior34-37.  Based on 
previous studies demonstrating that wavelengths near 800 nm could be used for relatively 
selective excitation of CFP over YFP38,39, we focused our evaluations of potential FRET 
acceptors on newer, improved variants of YFP.  Based on these studies, we identified 
monomeric (m)Turquoise35 and mVenus40 as optimal FPs for TPLSM.  We found that 
illumination at 810 nm efficiently excited mTurquoise with minimal direct excitation of 
mVenus33.  The selective excitation of mTurquoise at 810 nm allows ratiometric FRET 
measurements in vivo using TPLSM at a single excitation wavelength.  Moreover, the use of the 
cyan and yellow FPs is compatible with most TPLSM configurations.   
A critical step in the acquisition of measurements from FRET-based biosensors is 
validation of the sensitivity of the method.  It is necessary to demonstrate that measurements of 
subtle changes in the FRET ratio truly reflect the responses of the biosensor to cellular events.  
In general, FRET measurements should be reproduced using multiple methods.  For example, 
FRET estimates based on measurements of sensitized emission should be complemented with 
estimates from acceptor photobleaching or fluorescence lifetime measurements33.  Given the 
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inherent challenges of intravital microscopy our goal was to develop a protocol that would 
minimize the validation studies that must be conducted.  We accomplish this by providing a set 
of completely validated FRET standards, and a simple method by which the end-user can 
characterize and optimize FRET measurements in their own systems.   
 
Overview of the Procedure 
Here, we describe a protocol in which a TPLSM system can be optimized and validated for 
FRET measurements in studies of cultured cells, prior to studies in living animals (see Figure 
2).  We demonstrate intravital FRET biosensor imaging using an A kinase activity reporter 
(AKAR) biosensor of PKA activity, expressed by adenoviral transduction of the mouse liver. 
Our approach to intravital measurements of FRET-biosensor activity involves four stages: (i) 
characterization of the emission spectra and the determination of spectral crosstalk correction 
factors for the donor and emission FPs in the user’s system; (ii) validating the experimental 
system for measuring FRET using FRET standards expressed in cells in culture; (iii) validation 
of the FRET-biosensor for measurements from cells in culture; (iv) measurement of FRET-
biosensor responses in cells in living animals. 
Measurement of spectral crosstalk correction factors.  The imaging protocol described here 
exploits the relatively selective 2PE of mTurquoise35 over mVenus40 using illumination at 810 
nm, which enables the measurement of FRET ratios from single, two-channel images (Figure 
3). The accurate measurement of FRET efficiencies (EFRET), however, requires the application 
of correction factors for spectral crosstalk (Box 1).  These correction factors are entirely 
dependent upon the configuration and performance of the microscope system, and must be 
measured for each system.    
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Characterization and validation of FRET measurements using FRET standards.  The 
FRET standards are critical tools for verifying both the biological model and for optimizing the 
particular imaging system used for FRET measurements46.  By providing a range of calibrated, 
reproducible EFRET, the FRET standards allow the user to evaluate the performance of the 
system for the detection of FRET, and importantly, allow an assessment of the sensitivity of the 
measurements (described in Anticipated Results).  We have developed plasmids for a set of 
fully validated FRET standards, based upon mTurquoise and mVenus (see Figure 2, sequence 
information is provided in the Supplementary Sequence Archive, plasmids available from 
authors on request).  Measurements of EFRET obtained from living cells expressing these 
standards (using the approach described in Box 1) are used to validate and optimize the user’s 
system for detection of FRET in mTurquoise-mVenus-based biosensors. 
Validation of the FRET biosensor probe activity in cultured cells.  To verify and fully 
characterize the performance of the FRET biosensor in the user’s system, preliminary studies 
are conducted in cultured cells, which can be manipulated to identify the full range of FRET 
ratios provided by the biosensor under physiological conditions.  Here, an AKAR biosensor47,48 
with a reporter module consisting of mTurquoise and circular permuted (cp)Venus FPs 
(AKAR4.1)33 is used to monitor PKA activity in living cells.  The response of the AKAR4.1 
probe expressed in cells treated with a specific PKA agonist is used to characterize the 
performance of the system for measurements of changing FRET ratios. 
Measurements of biosensor probe activity in the living animal.  Once the imaging system 
has been validated using the FRET standards, and the performance of the biosensor has been 
verified in living cells in culture, the final step is to apply the information collected in the in 
vitro studies to use the FRET probe to assay cellular function in the living animal.  We use the 
11 
 
expression of Ad AKAR4.1 in the mouse liver to demonstrate the use of this protocol to 
measure the activity of the PKA pathway in vivo. 
Limitations of the approach   
 The protocol described here is designed for compatibility with the commonly available 
commercial TPLSM systems equipped with a single Titanium-sapphire laser, and detection 
pathways compatible with the emission spectra of cyan and yellow FPs.  We recognize that 
investigators may conduct their TPLSM studies on a shared instrument where the non-
descanned detectors may not be configured for the efficient collection of cyan and yellow 
fluorescence.  In this situation, it may be necessary to use the descanned detectors that are 
typically easier to configure.  Since descanned detectors are located far from the back aperture 
of the objective, they collect less of the fluorescence scattered in the tissue, and thus provide 
poorer reach into biological tissues than non-descanned detectors located adjacent to the back 
aperture of the objective.  The ideal design for a system dedicated to 2PE FRET studies would 
be one in which the non-descanned pathway was fitted with filters optimized for sensitive and 
specific detection of mTurquoise and mVenus. 
In addition, the objective lenses used to obtain subcellular resolution provide a field of 
view that is typically less than a millimeter across.  Therefore, it can be difficult to draw general 
conclusions about cellular function based upon observations collected within such a tiny 
window.  More significantly, the microscope samples only the most superficial layers of 
biological tissues.  Even TPLSM, which allows deeper imaging than confocal microscopy, is 
generally limited to depths of less than 100 microns into tissue.  Thus, TPLSM is incapable of 
analyzing populations of cells located deep in organs (e.g., renal medulla) or to evaluate 
physiological properties below the surface of tumors.  
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 Finally, the intravital setting presents significant challenges to the expression of 
fluorescent biosensor probes. Here, we use Ad transduction to achieve high level expression of 
a biosensor probe in the liver of mice.  The Ad provides robust, but transient, expression of the 
transgenes.  Further, there are typically inflammatory responses to the virus that can limit its use 
in prolonged studies.  These problems are largely overcome by adeno-associated virus (AAV) 
or lentivirus vectors, which can achieve persistent transgene expression with minimal 
inflammatory responses.  Importantly, there are many serotypes of AAV that differ in their 
capsid protein structures, and this enables distinct tissue tropism for the different serotypes20,41. 
Advantages  
A crucial component of this protocol is the use of the well-characterized FRET 
standards as a tool to validate that both the experimental model and microscope system are 
optimized for sensitive measurements of FRET (see Anticipated Results).  Therefore, it is 
necessary that the end user determines the corrected FRET efficiency for each of the standards 
to assess the performance of their system, and to compare their results with those obtained here 
(or from other studies if different standards are used).  The measurement of the FRET standards 
on the microscope system enables confirmation of the ratiometric FRET measurements acquired 
in vivo using the single wavelength 2PE of the biosensor probes.  The acquisition of single, 
two-channel images with TPLSM simplifies image collection, maximizing temporal resolution, 
and minimizing the number of in vivo studies.  The use of a single wavelength for 2PE offers 
additional advantages for the measurement of biosensor probe activity in intact tissue, avoiding 
the delay in the collection of ratio images and the effects of shifts in laser alignment at different 
wavelengths.   
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Several groups have described the use of fluorescence lifetime imaging as an effective 
approach for measuring FRET in vivo42-44.  The ratiometric approach offers a few key 
advantages over fluorescence lifetime-based approaches. First, it is easily implemented in most 
TPLSM systems, requiring no additional instrumentation.  Second, the ratiometric approach 
provides better temporal resolution; whereas fluorescence-lifetime measurements typically 
require image collection over tens of seconds, images for ratiometric measurements can be 
collected in less than a second. 
 We demonstrate the use of our approach to measure PKA activity in vivo.  However, we 
emphasize that this approach should be generalizable to other FRET-based biosensors, once the 
reporter module is modified to include mTurquoise and suitable acceptor.  For example, we 
have found very similar results using the optimized calcium biosensor probe, Twitch2b45.  Thus, 
with minimal effort the approach described here could be applied to many other biosensor 
probes by exchanging the earlier, more photo-labile, variants of the cyan FPs.  
 
MATERIALS 
 
REAGENTS 
 Dulbecco’s Modified Eagle’s Medium (DMEM, Fisher Scientific Inc. Cat. # 50-188-267FP) 
 Dulbecco’s Modified Eagle’s Medium without phenol red (Fisher Scientific Inc. Cat. # 
MT17205CV) 
 Fetal bovine serum (FBS, Atlanta Biologicals. Cat. # S11150) 
 Trypsin (Fisher Scientific Inc. Cat. # MT25-051-Cl, stored at -20º C).  
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 X-tremeGene HP DNA transfection reagent (Roche Diagnostics, Indianapolis, IN, Cat. 
#06366236001, made up fresh). 
 Appropriate biosensor construct. In the Procedure, we use the Adenovirus (Ad) CMV-Turq-
AKAR4 vector as an example, which was made as described previously49 (see 
Supplementary Sequence Archive). 
 HEK-293 cells (ATCC CRL-1573) Caution! – HEK-293 cells contain Adenovirus 5 DNA 
integrated into chromosome 19 and must be handled at Biosafety level 2.  The cell lines 
used in your research should be regularly checked to ensure they are authentic and are not 
infected with mycoplasma. 
 FP constructs. See Table 1. All FP constructs described here are available through the 
National Institutes of Health O’Brien Center for Advanced Renal Microscopic Analysis at 
Indiana University School of Medicine.  The plasmid sequences can be found in 
Supplementary Sequence Archive. 
Table 1: FP constructs required in the Procedure. 
Plasmid construct Purpose Additional comments 
mTurquoise N1 to determine donor spectral 
bleedthrough 
 
mVenus N1 to determine acceptor 
spectral bleedthrough 
 
Turquoise-TRAF-Venus 
(TTRAFV) 
Serves as a low FRET 
standard and is used to 
determine fractional 
excitation of Venus. 
Turquoise is separated from 
Venus by the TRAF2 
sequence.46  Typical EFRET is 
5-10%. 
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Turquoise-10aa-Venus 
(T10V) 
Serves as an intermediate 
FRET standard. 
Turquoise is separated from 
Venus by the sequence 
“SGLRSPPVAT”. Typical 
EFRET is 30-35%. 
Turquoise-5aa-Venus (T5V) Serves as a high FRET 
standard. 
Turquoise is separated from 
Venus by the sequence 
“SGLRS”.  Typical FRET 
efficiency (EFRET) is 40-45%. 
Turquoise AKAR4.1 Biosensor probe to detect 
protein kinase A activity. 
The AKAR4 biosensor48 
with Turquoise as the donor 
fluorophore. 
 Mice:  Caution! – Any experiments involving live mice must conform to relevant 
Institutional and National regulations.  All animal studies were approved by the Indiana 
University School of Medicine Institutional Animal Care and Use Committee and conform 
to the “Guide for the Care and Use of Laboratory Animals” published by the National 
Institutes of Health (NIH Publication No. 85-23, Revised 1996). 
 
EQUIPMENT 
 Laser scanning microscope compatible with two-photon excitation at 810 nm and two 
channel fluorescence detection in the approximate ranges of 454 – 494nm for detection of 
mTurquoise and 520 – 580nm for detection of mVenus. Our system is described in 
Equipment Setup.  
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 Image processing software capable of quantifying signal levels in user-identified regions of 
interest, such as ImageJ (https://imagej.nih.gov/ij/), Metamorph 
(https://www.moleculardevices.com/), or the microscope manufacturer’s software. 
 A laser power meter to measure the power at the specimen plane (PM100D power meter, 
Thorlabs, Newton, NJ). 
 
REAGENT SETUP 
HEK-293 cells: Human embryonic kidney (HEK)-293 cells are maintained in monolayer 
culture in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% (vol/vol) fetal 
bovine serum (FBS) at 37º C in a 5% (vol/vol) CO2 incubator, and harvested at 80% confluence 
by treatment with Trypsin.  The pH indicator dye Phenol red may cause background signals 
during imaging.  Therefore, prior to imaging the medium should be replaced with the same 
medium lacking the indicator.  
 
EQUIPMENT SETUP 
Intravital microscope system.  In our lab, IVM is conducted as previously described24 using a 
modified Olympus FV1000 spectral laser-scanning confocal microscope system, mounted on an 
Olympus IX81 stand, and modified for two-photon excitation.  Near-infrared illumination, 
provided by a MaiTai HP Ti-sapphire laser (Spectra-Physics, Santa Clara, CA) is attenuated 
using a Pockels cell electro-optical attenuator (Conoptics Inc., Danbury, CT), and the beam is 
expanded via a Keplerian collimator/beam expander.  Images are acquired using an Olympus 
25X, NA 1.05 XLPN water immersion objective (see Figure 1).  Fluorescence is collected 
using the Olympus FV1000 photomultiplier detectors on the descanned detection pathway.  The 
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FV1000 spectral detection system (spectral grating) is used to collect spectral data and to select 
emission wavelengths optimized for each fluorescent protein.   Laser power at the specimen 
plane is measured using a PM100D power meter, Thorlabs, Newton, NJ).  
 
PROCEDURE 
 
1| Transfection of cells with mTurquoise and mVenus plasmids.  18 – 24 h before 
transfection, plate cells HEK-293 cells in 500 μl complete growth medium at a density 
of 3.0 – 3.5 x105 cells/well in 4-well Lab-Tek II chambered coverglasses.  Incubate cell 
cultures overnight in a 5% (vol/vol) CO2 incubator.  The cells should be 50 – 85% 
confluent at the time of transfection, and each transfection should be performed in 
duplicate. 
 
2| Allow X-tremeGENE HP DNA Transfection Reagent, DNA and diluent (Opti-MEM. I 
Reduced Serum Medium or serum-free medium) to warm to room temperature (~ 21º 
C), and gently mix. 
3| For each transfection, place 300 μl diluent in a sterile tube. 
4| Add 3 μg of the appropriate plasmid DNA (see table below) to each transfection mix. 
Pipet gently to mix.  
Transfected 
plasmid(s) 
Step at which 
transfection 
performed 
Purpose  
mTurquoise 4 Determining optimal 
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settings for detection 
(step 11) and spectral 
bleedthrough (step 
13) 
mVenus 4 Determining optimal 
settings for detection 
(step 11) and spectral 
bleedthrough (step 
13) 
mTurquoise + 
mVenus 
4 Determining 
fractional excitation 
at 810nm (step 16) 
and EFRET (step 21) 
Turquoise-TRAF-
Venus (TTRAFV) 
4 Determining 
fractional excitation 
at 810nm (step 16) 
and EFRET (step 21) 
Turquoise-5aa-
Venus (T5V) 
4 Determining  EFRET 
(step 21) 
Turquoise-10aa-
Venus (T10V) 
4 Determining  EFRET 
(step 21) 
AKAR4.1 biosensor 
(or probe of interest) 
4 Biosensor probe for 
measurement of PKA 
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activity (step 27). 
 
5| Add 9 μl X-tremeGENE HP DNA Transfection Reagent to the diluted DNA. (3:1 ratio 
of reagent to DNA). Pipet gently to mix. 
6| Incubate for 15 – 30 min at room temperature. 
7| Add 75 μl of the appropriate transfection complex to cells in a drop-wise manner. 
8| Gently shake chambered coverglass to ensure even distribution, and then incubate the 
cells at 37º C in a 5% (vol/vol) CO2 for 24 – 48 h before imaging. 
 
System evaluation and optimization – determine the spectral ranges for the detectors (1.5-
2 hrs) 
9| Prepare TPLSM system.  At least 30 minutes prior to image acquisition, turn on the 
system according to the manufacturer instructions, to ensure that power and alignment 
are completely stabilized prior to image collection.  Tune and align laser at 810 nm.   
CRITICAL STEP:  Allow the laser to warm and stabilize for ~ 30 min before imaging 
to ensure the system is consistent for image collection. 
10| Prepare to collect images for measurement of spectral bleedthrough (SBT).  24 - 48 h 
after transfection of cells with mTurquoise or mVenus (at step 4), transfer transfected 
cells (from step 8) into a medium suitable for maintaining physiological pH in air, or 
into a chamber capable of maintaining 5% (vol/vol) CO2 environment.  Mount cells in a 
stage incubator set to maintain cells at 37 degrees C. 
11| Optimize the microscope settings for optimal detection of mTurquoise and mVenus 
emissions. Users with filter-based systems should follow Option A. Users with  spectral 
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fluorescence detectors should follow Option B to determine the spectral range settings 
for the imaging system.. 
CRITICAL STEP:  The SBT components that contaminate the FRET signal result from the 
donor (mTurquoise) emission that bleeds into the acceptor detection channel (DSBT), and the 
direct excitation of the acceptor (mVenus) at the donor excitation wavelength (ASBT).  It is 
necessary to correct for SBT in order to accurately determine FRET efficiency.  The SBT 
corrections are specific to each microscope system, and are entirely dependent on spectral or 
filter settings on the microscope, so it is critical to always verify these settings on multi-user 
microscope systems.  
 
(A) Verification of the set-up of filter-based systems 
(i) Select the correct emission filters for the cyan and yellow channels, and the 
appropriate dichroic mirror.   
(ii) Measure the signal from the cells expressing mTurquoise only and from cells 
expressing mVenus only (from step 8) to verify that the correct emission filters 
and dichroic mirrors are being used.  
(B)  Optimizing systems with spectral fluorescence detectors  
(i) Using cultured cells expressing mTurquoise only and cells expressing mVenus 
only (from step 8), set the illumination to 810 nm, adjust illumination levels to 
fill the dynamic range of the detectors without saturation and collect emission 
scans from approximately 420 – 600 nm. 
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(ii) Evaluate the emission spectra of mTurquoise and mVenus and identify the 
optimal wavelength ranges for selectively detecting mTurquoise and mVenus 
fluorescence emissions.  For our system, these ranges were determined to be 454 
– 494 for detection of mTurquoise and 520 – 580 for detection of mVenus 
(Figure 1). 
 
System evaluation and optimization – spectral bleedthrough and fractional excitation (1.5-
2 hrs) 
CRITICAL: This protocol uses a single excitation wavelength (810 nm) to measure FRET 
standard and biosensor activity.  The FRET standards are used for system validation, so it is 
necessary to determine the corrected EFRET for each standard excited at this wavelength (Step 
21). This requires the measurement and removal of the DSBT and ASBT (steps 13 and 16 and 
Box 1).  Since a single excitation wavelength is used, the determination of the ASBT also 
requires the estimation of the fractional excitation of Venus at 810 nm.  This is accomplished by 
measuring the average ICh2-810/ICh2-960 ratio from cells expressing a mixture of mTurquoise and 
mVenus (mTurquoise + mVenus), and the low FRET standard (Turquoise-TRAF-Venus, Step 
16).  
12| Collect images for measurement of SBT - Designate 810 nm as the illumination 
wavelength and select the optical configuration of the microscope system for optimal 
collection of CFP and YFP (determined in step 11A for users with filter-based systems) 
or set optical configuration according to the results obtained in step 11B (for users with 
spectral detection systems).  Adjust laser power to fill the dynamic range of the detectors 
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without saturation.  Collect two-channel images from living cells expressing 
mTurquoise only and from cells expressing mVenus only (from step 8).  
13| Image analysis for measurement of SBT.  Using image-processing software (e.g., 
ImageJ, Metamorph, or the microscope manufacturer’s software, identify regions-of-
interest in several cells expressing mVenus only and for each region measure the signal 
levels in the CFP and YFP channels.  Correct these measurements for background by 
subtracting measurements obtained from nearby regions lacking fluorescence.  For each 
cell, measure ASBT as the ratio of corrected measures obtained in the CFP channel to 
those obtained in the YFP channel.  ASBT measurements are used to derive the 
correction factor A (Box 1), which is defined as the fraction of the signal in the acceptor 
channel that results from the direct excitation of mVenus at 810 nm.  ? Troubleshooting 
14| Using image-processing software, identify regions-of-interest in several cells expressing 
mTurquoise only.  For each region measure the signal levels in the CFP and YFP 
channels.  The images are corrected for background by subtracting measurements 
obtained from nearby regions lacking fluorescence.  For each cell, measure DSBT as the 
ratio of corrected measures obtained in the YFP channel to those obtained in the CFP 
channel.  DSBT measures are used to derive the correction factor B (Box 1), which is 
defined as the fraction of the signal in the acceptor channel that results from the 
bleedthrough of the mTurquoise emission. 
15| Collect images for measurement of fractional excitation of mVenus at 810 nm. Using the 
same wavelengths, collect images of living cells expressing both mTurquoise and 
mVenus under conditions of minimal FRET (e.g., a mixture of the two, or a low-FRET 
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standard, from step 8) first with illumination at 810 nm, and then again using 
illumination at 960 nm.  Laser power at 960 nm should be adjusted to be equivalent to 
that used at 810 nm, as measured with a laser power meter at the specimen plane.  ? 
Troubleshooting 
CRITICAL STEP:  Tuning a titanium-sapphire laser to different wavelengths may lead to 
differences in laser alignment that can impact quantitative measures.  It is critical to ensure that 
laser alignment is unaffected, or corrected, when changing between 810 and 960 nm. 
16| Image analysis for measuring fractional excitation of mVenus at 810 nm.  Using image-
processing software (e.g., ImageJ, Metamorph or the microscope manufacturer’s 
software), identify regions-of-interest in several cells expressing mVenus and for each 
region measure the signal levels in the YFP channels when excited at 810 nm and when 
excited at 960 nm.  Correct these measurements for background by subtracting 
measurements obtained from nearby regions lacking fluorescence.  For each cell, 
measure the ratio of corrected signals obtained at 810 nm illumination to those measured 
at 960 nm.  This ratio is used, along with ASBT, to derive the correction factor A.  The 
corrected FRET signal (FRETcorr) is determined by subtracting the crosstalk components 
A and B from the raw FRET signal (donor excitation, acceptor emission (Box 1).   
 
System validation - Measure FRET in living cells expressing FRET-standard constructs – 
3-4 hrs 
CRITICAL: The performance of the system is validated by measurement of FRET in cultured 
cells expressing the fully characterized FRET standard constructs. The determination of EFRET 
for the known FRET standards enables the user to assess the performance of their system, and 
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to compare their results with those obtained here (or from other studies if different standards are 
used).  To ensure that physiological measurements are not compromised by potential changes in 
the laser, optics, or detectors, data should be collected for FRET standards with each 
physiological study. 
17| Image collection for measurements of FRET standards.  24 - 48 h prior to imaging, 
transfect HEK293 cells (as described in Steps 1-8) with the FRET standard constructs - 
mTurquoise-TRAF-mVenus, mTurquoise-5AA-Venus, mTurquoise-10AA-Venus and a 
1:1 mixture of mTurquoise and mVenus (see step 4).   
18| Prepare the TPLSM system for imaging, as described in Step 9. 
19| Transfer transfected cells into a medium suitable for maintaining physiological pH in 
air, or into a chamber capable of maintaining 5% (vol/vol) CO2 environment.  Mount 
cells in a stage incubator set to maintain cells at 37 degrees C.  ? Troubleshooting 
20| Using the same laser power and emission wavelength settings used in steps 12 and 15, 
collect two-channel images of cells expressing each of the FRET standard constructs and 
cells co-expressing mTurquoise and mVenus (see step 4). 
CRITICAL STEP:  Transient co-transfection of cells with a mixture of the mTurquoise and 
mVenus plasmids will produce highly variable relative expression levels of the two different 
FPs.  For this protocol, it is important to pre-select cells for imaging that have intensity levels in 
both channels that are similar to the low FRET efficiency standard (mTurquoise-TRAF-
mVenus, which has a fixed 1:1 ratio of the donor and acceptor with little donor quenching). 
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21| Image analysis for measurements of FRET standards.  Using image-processing 
software, identify regions-of-interest in several cells expressing fluorescent proteins and 
for each region measure the signal levels in the CFP and YFP channels.  Correct these 
measurements for background by subtracting measurements obtained from nearby 
regions lacking fluorescence.  For each cell, measure the FRET ratio and calculate EFRET 
(Box 1). 
CRITICAL STEP:  The 2PE method described here should readily distinguish the three FRET 
standards with the different linker lengths from one another based on the measured EFRET (see 
ANTICIPATED RESULTS).  It is critical to use this approach to demonstrate that the TPLSM 
system is properly set up to obtain accurate measurements of EFRET, and is capable of high 
sensitivity measurements from the biosensor probes in living cells. 
 
Validate the FRET biosensor - Measure the biosensor probe FRET response in cultured 
cells  - 5 hrs 
CRITICAL: It is important to validate the performance of the biosensor in a cell model prior to 
studies in more complex systems.  The response of the biosensor probe is evaluated in living 
cells following treatment with agents known to stimulate the relevant physiological response 
pathway.  Here, the PKA agonist forskolin (Fsk) is used to test the response of the AKAR4.1 
biosensor to PKA activation. 
22| Image collection for measurements of FRET biosensor responses.  24 - 48 h prior to 
imaging, transfect HEK293 cells with the FRET biosensor (here, AKAR4.1) as 
described in steps 1-8. 
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23| Prepare the TPLSM system for imaging, as described in Step 9. 
24| Transfer transfected cells into a medium suitable for maintaining physiological pH in 
air, or into a chamber capable of maintaining 5% (vol/vol) CO2 environment.  Mount 
cells in a stage incubator set to maintain cells at 37 degrees C.  ? Troubleshooting 
25| Using laser power and emission wavelength settings used in steps 12, 15 and 17, collect 
a series of two-channel images of a field of cells expressing AKAR4.1 to establish 
baseline measurements. 
26| Collect a series of images before and after activating the biosensor probe.  Here, images 
were collected at 30 sec intervals before and after addition of Fsk to the culture medium 
(final concentration of 24 M).  Fsk-mediated activation of PKA is expected to induce a 
rapid and significant increase in the Venus to Turquoise emission ratio (see 
ANTICIPATED RESULTS). 
27| Image analysis for measurements of FRET biosensor responses.   Using image-
processing software, identify regions-of-interest in several cells expressing AKAR4.1 
and for each region measure the signal levels in the CFP and YFP channels.  Correct 
these measurements for background by subtracting measurements obtained from nearby 
regions lacking fluorescence.  For each cell at each time point, measure the normalized 
Venus to Turquoise emission ratio. 
CRITICAL STEP:  It is important to verify the function of the FRET-based biosensor probes 
using other methods, such as fluorescence lifetime imaging microscopy or acceptor 
photobleaching measurements.  Additionally, it is important to demonstrate that the biosensor is 
reporting the correct cellular activity.  Treatment of cells with unrelated signaling molecules, or 
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antagonists to the specific cellular pathway should not elicit the biosensor response.  Moreover, 
point mutations in the bioactive linker (phosphorylation or binding sites) should abolish the 
changes in the probe response.  
 
Measure the biosensor probe FRET response in the organ of a living animal – Intravital 
microscopy - 7 hrs 
CRITICAL: Once the biosensor has been validated, the 2PE ratiometric method can be used to 
measure biosensor probe activity in the targeted organ in a living animal.  Here, we demonstrate 
the approach by measuring the effect of glucagon on PKA activity in cells in the intact mouse 
liver in mice transduced with the Ad AKAR4.1 vector.  
 
28| Transduction of mice with a FRET biosensor. 7 days prior to imaging, introduce 0.2 ml 
of the Ad AKAR4.1 vector (4.8 x 1010 particles) into mice by tail vein injection, using 
standard methods (e.g., http://www.procedureswithcare.org.uk/intravenous-injection-in-
the-mouse/). 
Caution! – All animal studies must be approved by the Institutional Animal Care and 
Use Committee and must conform to the National regulations. Studies of animals 
transduced with adenovirus must be conducted in compliance with institutional biosafety 
standards. 
29| Image collection of FRET biosensor responses in the liver of a living mouse. 
Physiological manipulations and animal preparations will vary according to the study.  
To prepare for activation of PKA in liver via glucagon53, withdraw food from mice 3 h 
prior to scheduled imaging.  
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30| Prepare the TPLSM system for imaging, as described in Step 9. 
31| Externalize the left lateral lobe of the liver and prepare for IVM imaging through a glass 
bottom plate using methods previously described24.   
32| Place the animal on the warmed microscope stage, identify a field of hepatocytes 
expressing AKAR4.1 and, using the same microscope settings used in steps 12, 15, 17 
and 26, collect a series of 3D image volumes (10 planes spanning 10 microns) in CFP 
and YFP channels to establish the baseline ratio.  3D stacks are collected to ensure 
sequential capture of hepatocyte cytosols despite residual vertical motion of the liver 
because of respiration. 
33| Continue to collect 3D image volumes during and following IP injection of glucagon 
(200 μg/kg) to monitor the increase in the FRET ratio resulting from activation in PKA. 
34| Image analysis of FRET biosensor responses in the liver of a living mouse. Using 
image-processing software, align and assemble image stacks into a sum of all planes 
for each channel and each time point. 
35| Identify regions-of-interest in several cells expressing AKAR4.1 that display 
relatively uniform fluorescence.  For each region measure the signal levels in the CFP 
and YFP channels. Correct these measurements for background by subtracting 
measurements obtained from nearby regions lacking fluorescence.  For each cell at 
each time point, measure the Venus to Turquoise emission ratio. 
36| Pool and normalize the measured emission ratio data for all regions of interest.  ? 
Troubleshooting 
TROUBLESHOOTING 
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Troubleshooting advice can be found in Table 2. 
 
TIMING [Note from editor: please update and correct step numbers in section below 
to reflect changes to the Procedure] 
Steps 1-8, Cell transfection:  ~ 1 h, approximately 24 - 48 h prior to imaging 
Steps 9-10, Prepare TPLSM system for imaging:  ~ 0.5 h 
Optional Step 11, Determine the spectra ranges of the detector channels; ~ 1 h 
Steps 12, Image collection for measurement of SBT: ~ 1 h.  
Steps 13-14, Image analysis for measurement of SBT: ~ 1 h. 
Step 15, Image collection for measurement of fractional excitation of mVenus at 810 nm: ~ 1 h 
Step 16, Image analysis for measurement of fractional excitation of mVenus at 810 nm: ~ 1 h 
Steps 17-20, Image collection for measurement of FRET standards in cultured cells: ~ 2 h   
Step 21, Image analysis for measurement of FRET standards in cultured cells: ~ 4 h 
Steps 22-26, Image collection for measurement of FRET biosensor responses in cultured cells: 
~ 2 h   
Step 27, Image analysis for measurement of FRET biosensor responses in cultured cells: ~ 3 h 
Step 28, Transduction of mice with a FRET biosensor: ~ 1 h 
Steps 29-33, Image collection for measurement of FRET biosensor responses in living mouse: ~ 
4 h 
Steps 34-36, Image analysis for measurement of FRET biosensor responses in living mouse: ~ 4 
h 
Box 1, Analysis of spectral bleedthrough for the determination of FRET efficiency: ~ 1 h 
ANTICIPATED RESULTS 
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Measurements of the FRET standards using 2PE.  The FRET standards are used to 
demonstrate that the experimental model and microscope system are optimized for sensitive 
measurements of EFRET in living cells (Steps 17-21).  If the SBT corrections are accurate (Box 
1), then there should be very little energy transfer detected in cells that express a mixture of the 
unlinked mTurquoise and mVenus.  The low FRET-efficiency standard, mTurquoise-TRAF-
mVenus should also have a low, but measurable EFRET (~5%)33,46,52.  In contrast, measurements 
from the cells expressing the highest EFRET standard, mTurquoise-5AA-Venus produce EFRET of 
about 45%.  Critically, measurements from cells expressing the mTurquoise-10AA-Venus 
standard are expected to be about 36%, and should be readily distinguishable from the FRET 
standard with the shorter linker (Figure 4).  These FRET standards allow the validation of the 
imaging system, and provide a clear indication of the sensitivity of the measurements.  The 
FRET standards also provide a control for identifying changes in performance of the laser, 
optics, or detectors that may compromise measurements under physiological conditions. 
2PE measurements of FRET-based biosensor probe activities in cultured cells.  Biosensor 
validation is accomplished in studies in cultured cells expressing the biosensor that are treated 
with established methods to activate the cell-signaling event.  For our studies, we transfected 
HEK293 cells with AKAR4.1 and monitored emissions in the cyan (454 – 494 nm) and yellow 
(520 – 580 nm) channels under illumination at 810 nm (Step 22-27).  After collecting a series of 
baseline images, the PKA agonist forskolin (Fsk) was added to a final concentration of 24 M.  
As expected, forskolin induced a rapid and pronounced (1.4-fold) increase in the emission ratio 
of Ven/Turq (Figure 5).   
2PE measurements of FRET-based biosensor probe activities in living animals.  After 
validation of the microscope system and the biosensor, studies are next conducted in living 
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animals.  For our studies, we took advantage of the robust tropism of adenovirus for the mouse 
liver following tail vein injection20 (Step 28).  Seven days after injection with Ad AKAR4.1, the 
mice were fasted for 3 h, prepared for IVM and then imaged as described above (Steps 29-33).  
Baseline images were collected, and imaging was continued after IP injection of glucagon (200 
μg/kg), a treatment that has been previously shown to rapidly stimulate both cAMP and PKA in 
hepatocytes of fasted mice53.  Similar to the results obtained with HEK-293 cells treated with 
Fsk, glucagon treatment in the living mouse induced a rapid 1.4 fold change in emission ratio of 
Ven/Turq (Figure 6), indicating a rapid and sustained activation of PKA.  A certain degree of 
cell-cell variability can be expected from cells in vivo; our earlier measurements33 of 32 
hepatocytes, from three separate studies ranged from 1.14 to 1.827.   
Note: Any Supplementary Information and Source Data files are available in the online version 
of the paper. 
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Box 1: Analysis of spectral bleedthrough for the determination of FRET efficiency.  
Digital Image Analysis - Timing ~ 1.5 h 
The optical pathway of the microscope system must be optimized for the detection of 
the mTurquoise-mVenus based biosensor probe when excited at 810 nm.  This is achieved 
by imaging cells that express either mTurquoise or mVenus alone (Procedure Steps 12-14).  
Spectral scanning on systems with spectral detectors, or careful selection of emission filters 
on filter-based systems will allow the user to adjust the optimal bandwidth for detection of 
the donor and acceptor signals (Procedure step 11).  Once the donor and acceptor emission 
bandwidths are set, it is then necessary to measure the contributions of spectral 
bleedthrough (SBT) to the signals detected in the FRET channel (excitation 810 nm, 
acceptor emission).  The subtraction of the SBT signals from the signal that is detected in 
the FRET channel (FRETraw) provides the corrected FRET (FRETcorr) signal50:    
  FRETcorr = IFRET  – A*IFRET  – B*ITurq    (Eq 1) 
Correction for acceptor spectral bleedthrough (ASBT):  The ASBT signal arises from 
the direct excitation of mVenus at 810 nm.  The correction factor A (Eq 1) is used to 
remove ASBT.  Measurements from cells expressing only mVenus are obtained using both 
810 nm and 960 nm excitation to determine the fraction of the acceptor signal that arises 
from the direct excitation of mVenus at 810 nm.  For our system, we determined that the 
ASBT fraction was 0.030.  Because this protocol uses a single excitation wavelength (810 
nm) to measure FRET standard and biosensor activity, it is also necessary to approximate 
the intensity in the acceptor channel (Ch2-960) from the measurement at 810 nm (i.e., the 
fractional excitation of Venus at 810 nm).  This is accomplished by measuring the average 
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ICh2-810/ICh2-960 ratio from cells expressing a mixture of mTurquoise and mVenus, and cells 
expressing the low-FRET standard (Turquoise-TRAF-Venus). For our system the average 
ratio was 0.344.  Therefore, multiplication of the acceptor intensity measured with 
excitation at 810 nm by 2.91 (1/0.344) provides an approximation of the intensity in the 
acceptor channel to allow correction for ASBT.  For our microscope system, the correction 
factor A is 2.91 x 0.03 = 0.087.  
Correction for donor spectral bleedthrough (DSBT):  The correction factor B (Eq 1) is 
used to remove DSBT, the signal detected in the acceptor channel that results from donor 
emission bleedthrough, and is determined from cells expressing only mTurquoise.  
Measurements from the donor-alone cells excited at 810 nm allowed us to determine the 
donor bleedthrough fraction was 0.295 on our system.  Thus, the FRETcorr can be 
determined by:  
  2PE FRETcorr = IFRET  – 0.087*IFRET – 0.295*ITurq    (Eq 2) 
Determining FRET efficiency (EFRET) for the FRET standards:  The validation of the 
imaging system is accomplished by measurement of the FRET standards.  Here, 
measurements are acquired from cells expressing a low EFRET standard (mTurquoise-
TRAF-mVenus), and two high EFRET standards (mTurquoise-5AA-Venus and mTurquoise-
10AA-Venus) as described in ANTICIPATED RESULTS.  The low EFRET standard 
provides an indication of the threshold of detection, while the measurements from the two 
different high EFRET standards allow the user to assess the sensitivity of the system. 
The EFRET is calculated as previously described33,50,51 using the equation: 
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  E = Dlost / Dtotal = Dlost / (Dlost + Dremains)  (Eq 3) 
Where  
  Dlost = FRETcorr*(QYd / QYa)*(Sd / Sa)*(Gd / Ga)  (Eq 4) 
and  
  Dremains = ITurq-810       (Eq 5)  
QYd and QYa denote the quantum yields of the donor and acceptor, respectively, where the 
quantum yield ratio for mTurquoise and mVenus is 1.47435,40.  Sd and Sa denote the spectral 
sensitivities of the donor and acceptor channels.  The Sd / Sa ratio is approximated by the 
bandwidth ratio of channel 1 and channel 2.  Gd and Ga are the detector gains for the donor 
and acceptor emission channels, and were set to a scaling factor of 1 for all measurements. 
END OF BOX 1 
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Table 2| Troubleshooting table.  
 
Step Problem Possible reason Solution 
12, 15, 
17, 22 
Cells do not adhere to the 
cover slip properly, or they 
are not healthy 
Cover slips are not coated 
with appropriate matrix.  
 
Inappropriate culture 
conditions 
Coat cover slips with poly-
d-lysine or collagen.  
 
Ensure that the culture 
conditions are optimized 
for the cell line used. 
12, 15, 
17, 22 
Inadequate expression of 
fluorescent proteins in 
cultured cells 
The transfection agent 
(FuGENE, Lipofectamine, 
X-tremGene HP) or DNA 
plasmid concentration or 
their ratio is not optimized 
Follow the transfection 
agent manufacturer’s 
recommendations to vary 
the ratio of DNA: 
transfection agent or 
concentrations of DNA 
and/or transfection agent 
12, 15, 
17, 22, 
29 
Photobleaching is observed The power of the excitation 
light is too high 
Optimize the optical path 
and/or reduce laser power. 
12, 15, 
17, 22, 
29 
The signal fluctuates 
during TPLSM data 
acquisition 
The laser illumination is 
unstable.  
Ensure that laser is 
warmed for ~30 min prior 
to imaging.  Ensure that 
room temperature is stable. 
17, 22, 
29 
 FRET measurements are 
obscured and/or altered by 
cell or tissue 
autofluorescence.  
Components in the specimen 
have fluorescence excitation 
properties at the donor 2PE 
wavelength.   
Avoid media with 
indicator dyes. Change 
range of spectral detector 
or change bandpass filter 
for acceptor and/or donor 
emissions to minimize 
interference.  Collect 
images from FRET 
standards expressed in the 
same cells or tissues used 
in studies of physiology. 
11 Substantial bleedthrough of 
the acceptor signal in the 
donor channel is observed.  
Spectral bandwidth of donor 
channel extends too far into 
the range of the acceptor 
emissions.  Spectral 
bandwidth of acceptor 
channel is too wide or 
inappropriate dichroic mirror 
used. 
Change range of spectral 
detector or change 
bandpass filter for acceptor 
and/or donor emissions. 
11 Substantial bleedthrough of 
the donor signal into the 
acceptor channel.  
Spectral bandwidth of 
acceptor channel extends too 
far into the range of the 
Change range of spectral 
detector or change 
bandpass filter for acceptor 
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Excessively high value of 
correction factor “B”. 
donor emissions or 
inappropriate dichroic mirror 
used.   
and/or donor emissions. 
21 Spatial variation in ratios 
measured for the FRET 
standards 
Chromatic aberration 
 
 
 
Variable illumination across 
the field 
 
 
 
Variable background across 
the field 
 
 
Spatial variation in 
photobleaching. 
Choose chromatically 
corrected optical 
components. 
 
Ensure homogeneous 
illumination; restrict 
measurements to 
homogenous region. 
 
Use local background 
subtraction for 
quantifications. 
 
Minimize illumination 
levels, minimize time 
spent identifying fields to 
collect. 
21 FRET standards fail to 
produce the expected 
EFRET. 
Low levels of probe 
expression resulting in high 
background contributions, 
errors in image processing, 
or errors in SBT corrections.  
 
 
 
 
 
Deterioration of TPLSM 
system performance.  
It is critical to verify the 
FRET measurements of 
the standards by multiple 
methods (e.g., sensitized 
emission, acceptor 
photobleaching, 
fluorescence lifetime)33.  
The different methods 
should provide the same 
EFRET for the standards.   
 
If comparison with 
previous studies indicates 
a decline in the imaging 
system performance, check 
the optical path for 
alignment issues, check all 
filter settings, and measure 
laser power at the 
specimen plane to verify 
that it is the same as 
previous studies.  If this 
fails, call for microscope 
service. 
26, 27 Biosensor fails to respond Cells are not healthy. Ensure that cells are 
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as expected to 
physiological stimulation. 
 
 
Probe activator is ineffective. 
 
 
 
 
Deterioration of TPLSM 
system performance. 
healthy (see steps 1-2). 
 
Ensure that probe activator 
is fresh, appropriately 
handled and used at the 
correct concentration.   
 
If comparison with 
previous studies indicates 
a decline in the imaging 
system performance, check 
the optical path for 
alignment issues, check all 
filter settings, and measure 
laser power at the 
specimen plane to verify 
that it is the same as 
previous studies. If this 
fails, call for microscope 
service. 
29, 36 Inadequate fluorescence 
signal levels in animal. 
Inadequate expression of 
fluorescent proteins.   
 
Excessive depth-dependent 
attenuation of fluorescence. 
Measure viral titer. 
 
 
Reduce the depth of image 
collection.  Increase 
illumination level. 
29, 36 Fluorescence image 
decreases in intensity 
and/or clarity over time. 
Water has evaporated from 
water immersion objective. 
Replenish water more 
frequently.  Consider 
switching to oil, glycerol 
or silicon-oil immersion 
objectives. 
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FIGURE LEGENDS 
Figure 1| Schematic overview of the Procedure to measure biosensor activity in the living 
animal.  Following viral transduction of a biosensor probe in mice, the procedure is used to 
monitor the activity of the probe in the anesthetized animal.  The procedure uses selective 2PE 
of mTurquoise at 810 nm to make ratiometric FRET measurements in vivo.  To image probe 
activity in the liver, the left lateral lobe of the liver was carefully lifted and secured to a glass 
bottom plate.  The mouse is then placed ventral side down on a heated microscope stage and 
covered with a warming blanket, and the liver is imaged using a long working-distance water-
immersion objective.  
 
Figure 2| Diagram of the flow of the Procedure.  The Procedure starts with transfection of 
cells (Procedure steps 1-8) with a series of standards that are used to evaluate and optimize the 
TPLSM system, and to determine the SBT components when using 2PE at 810 nm (Procedure 
steps 10-16).  Then, the FRET standards are used to evaluate the sensitivity of the system for 
the accurate measurement of EFRET (Procedure steps 17-21).  The biosensor probe of interest is 
then verified in a cell model by measuring changes in the Venus to Turquoise ratio over time in 
response to suitable activators of the targeted signaling pathway (Procedure steps 22-27).   Once 
the system and biosensor have been verified, studies in the living animal are conducted 
(Procedure steps 28-36). 
 
Figure 3| 2PE spectral scanning of the indicated FPs expressed individually in living HEK-
293 cells.  The relative 2PE spectral scans for (a) mTurquoise and (b) mVenus, were acquired 
from living cells by measuring fluorescence emissions over a range of excitation wavelengths at 
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a constant laser power and a detector scaling factor of 1; the red bar indicates excitation at 810 
nm used in this protocol. In order to provide fluorescence excitation spectra that are 
independent of variations at the output of the laser at different wavelengths, spectral variation in 
laser power was eliminated by adjusting laser power to a constant value at each wavelength, as 
measured using a PM100D power meter with  correction (Thorlabs, Newton, NJ), mounted on 
the microscope stage33. The emission signals at the different excitation wavelengths were 
simultaneously detected in channel 1 (cyan, 454 – 494 nm) and channel 2 (yellow, 520 – 580 
nm), and the images are acquired at each wavelength step as described in the Experimental 
Design. [Adapted from ref 33]   
 
Figure 4| FRET ratio images of HEK-293 cells expressing the indicated FRET standard 
probes.  Cells were excited by illumination at 810 nm and the mTurquoise (donor) intensity 
was measured in channel 1(454 – 494 nm), while mVenus (acceptor) intensity was measured in 
channel 2 (520 – 580 nm).  The FRET ratio images obtained from representative cells 
expressing the different FRET standard fusion proteins are shown (scale bar is 10 μm). 
[Adapted from ref 33]   
 
Figure 5| Ratiometric FRET measurements from HEK-293 cells expressing the AKAR4.1 
biosensor probe.  The cells are illuminated at 810 nm and the emission signals are 
simultaneously measured in the mTurquoise (donor) channel (454 – 494 nm) and the mVenus 
(acceptor) channel (520 – 580 nm).  The cells were treated with protein kinase A (PKA) 
activator Forskolin (Fsk) to elicit changes in the FRET signal from the AKAR4.1 biosensor 
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probe.  (a) FRET ratio images of cells prior to (pre-treatment) and 3 min after Fsk treatment 
(scale bar is 10 μm).  (b) The cells were treated with Forskolin (Fsk) at time zero and the 
acceptor to donor ratio (Ven/Turq) was measured every thirty seconds for ten minutes.  The 
Ven/Turq ratio was determined from eleven cells (± SE) as described in Box 1. [Adapted from 
ref 33]   
 
Figure 6| Using TPLSM to measure the response of the AKAR4.1 biosensor to glucagon in 
hepatocytes in the intact mouse liver.  The Ad AKAR4.1 viral particles were introduced by 
tail vein injection, and resulted in extensive expression in the liver 7 days later. (a) Ratio images 
from a single image plane in mouse liver at the indicated time points (scale bar is 10 μm). (b) 
The mouse was treated by IP injection with glucagon (200 μg/kg) at time zero and the acceptor 
to donor ratio (Ven/Turq) was measured every fifteen seconds for ten minutes.  The Ven/Turq 
ratio was determined as described in Box 1, and the results are from the 10 individual cells (± 
SE). [Adapted from ref 33]  All animal studies were approved by the Indiana University School 
of Medicine Institutional Animal Care and Use Committee and conform to the “Guide for the 
Care and Use of Laboratory Animals” published by the National Institutes of Health (NIH 
Publication No. 85-23, Revised 1996). 
 
Supplementary Information 
Supplementary Sequence Archive. DNA sequence information for plasmids used in this 
protocol (see Table 1). 
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